Management of hyperphosphataemia of chronic kidney disease: Lessons from the past and future directions

Nephrology Dialysis Transplantation

Volumn 17, Issue 7, 2002, Pages 1170-1175

  Malluche, Hartmut H ^a   Mawad, Hanna ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aluminium; Hyperphosphataemia; Lanthanum; Magnesium; Renal bone disease; Sevelamer hydrochloride

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SALT; IRON DERIVATIVE; LANTHANUM; LANTHANUM CARBONATE; LANTHANUM CHLORIDE; MAGNEBIND; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM SALT; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DISEASE; BRAIN DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; MEDICAL RESEARCH; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RENAL OSTEODYSTROPHY; STANDARD; TREATMENT OUTCOME; BLOOD; CHRONIC KIDNEY FAILURE; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ACETATES; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHORUS; PHOSPHORUS METABOLISM DISORDERS;

EID: 0036020909     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.7.1170     Document Type: Article

References (56)

1. The dialysis encephalopathy syndrome. Possible aluminum intoxication
2. Aluminum-related bone disease
3. Aluminum-induced dialysis osteodystrophy: The demise of 'Newcastle bone disease'?
4. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients
5. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis
6. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
7. Cardiac valve calcification in hemodialysis patients: Role of calcium-phosphate metabolism
8. Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium-based phosphate binders
9. Risk of adynamic bone disease in dialyzed patients
10. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease
11. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using 'proportional reduction' of dietary phosphorus intake
12. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibility
13. An evaluation of a new and effective phosphorus binding agent
14. Hyperphosphatemia
15. Hyperaluminaemia from aluminum resins in renal failure
16. Evidence for aluminum accumulation in renal failure
17. Calcium acetate, an effective phosphorus binder in patients with renal failure
18. Use of calcium carbonate as a phosphate binder in dialysis patients
19. Alternative phosphate binders in dialysis patients: Calcium carbonate
20. Pathogenesis of secondary hyperparathyroidism
21. Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate and vitamin D
22. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro
23. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
24. Are we mismanaging calcium and phosphate metabolism in renal failure?
25. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients
26. Clinical epidemiology of cardiovascular disease in chronic renal disease
27. Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients
28. Risk factors for renal osteodystrophy: A multivariant analysis
29. Renal bone disease 1990: An unmet challenge for the nephrologist
30. The spectrum of bone disease in end-stage renal failure-an evolving disorder
31. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease
32. RenaGel, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
33. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients
34. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
35. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients
36. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis
37. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis
38. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia
39. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study
40. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation
41. Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients
42. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption
43. Calcitriol, lanthanum carbonate and other phosphate binders in the management of renal osteodystrophy
44. Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients
45. Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis
46. Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite
47. An assessment of the effects of lanthanum on bone in a chronic renal failure (CRF) rat model
48. Cytotoxicity of the rare earth metals cerium, lanthanum and neodymium in vitro: Comparisons with cadmium in a pulmonary macrophage primary culture system
49. Neurotoxicity of lanthanum chloride in newborn chicks
50. Effects of lanthanum in cellular systems. A review
51. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients
52. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
53. Understanding and managing hyperphosphatemia in patients with chronic renal disease
54. Toward a new treatment paradigm for hyperphosphatemia in chronic renal disease
55. The role of bone biopsy in clinical practice and research
56. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients